Biography

Megan A. Mullins, PhD, MPH,  joined the faculty in April 2022. Dr. Mullins received both her MPH and PhD in Epidemiologic Sciences from the University of Michigan School of Public Health. She completed post-doctoral training at the University of Michigan’s Rogel Cancer Center where she was a T32 fellow in cancer care delivery research and the inaugural Cancer Care Delivery Research Fellow at NRG Oncology, a research base in the NCI Community Oncology Research Program (NCORP).

Dr. Mullins’ research program is focused on improving the quality and equity of cancer care for people with advanced stage cancers. Her work is centered in three broad areas: 1) populations who are at high risk for poor cancer outcomes (e.g. older adults with cognitive impairment, racial/ethnic minorities, and sexual and gender minorities); 2) goal concordant care; and 3) palliative and end-of-life care. Dr. Mullins uses mixed-methods approaches for care delivery research to inform the implementation of evidence-based interventions. She has specific expertise in the analysis of large population-based and medical claims data, in-depth interviewing, surveying patients and providers, and health disparities research.

Dr. Mullins is currently the Principal Investigator of a national pilot study funded by NRG Oncology to evaluate barriers and facilitators to sexual orientation and gender identity (SOGI) data collection in NCORP practices and develop a stakeholder engaged implementation strategy for routine SOGI data collection.

Education

Graduate School
Uni of Michigan - Ann Arbor (2015), Epidemiology
Graduate School
Uni of Michigan - Ann Arbor (2020), Epidemiology

Research Interest

  • Advanced/metastatic cancer
  • Cancer care delivery research
  • End-of-life care
  • Goal concordant care
  • Gynecologic cancers
  • Implementation science
  • Palliative care

Publications

Featured Publications LegendFeatured Publications

Physician Influence on Variation in Receipt of Aggressive End-of-Life Care Among Women Dying of Ovarian Cancer.
Mullins MA, Uppal S, Ruterbusch JJ, Cote ML, Clarke P, Wallner LP, JCO Oncol Pract 2022 Mar 18 3 e293-e303
Validation of Self-reported Cancer Diagnoses Using Medicare Diagnostic Claims in the US Health and Retirement Study, 2000-2016.
Mullins MA, Kler JS, Eastman MR, Kabeto M, Wallner LP, Kobayashi LC, Cancer Epidemiol Biomarkers Prev 2022 01 31 1 287-292
Trends and racial disparities in aggressive end-of-life care for a national sample of women with ovarian cancer.
Mullins MA, Ruterbusch JJ, Clarke P, Uppal S, Wallner LP, Cote ML, Cancer 2021 07 127 13 2229-2237
Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.
Mullins MA, Peres LC, Alberg AJ, Bandera EV, Barnholtz-Sloan JS, Bondy ML, Funkhouser E, Moorman PG, Peters ES, Terry PD, Schwartz AG, Lawson AB, Schildkraut JM, Cote ML, Cancer 2019 12 125 24 4442-4451